Can doctors watch brain metastases instead of zapping them?

NCT ID NCT07827001

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers at the University of California, Irvine are testing whether patients with brain metastases can safely skip immediate surgery or radiation and instead have their tumors monitored with regular imaging, cognitive tests, and quality-of-life questionnaires. All participants receive systemic therapy that penetrates the central nervous system. The trial enrolls 12 adults with metastatic cancer that has spread to the brain and measures whether patients can be enrolled, complete surveillance scans, and finish the assessments. It also tracks safety events linked to brain tumor growth during systemic treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an active surveillance approach that monitors brain metastases with imaging, cognitive tests, and quality-of-life questionnaires instead of immediate surgery or radiation
What this could lead to
If it works, this could offer a way to delay or avoid surgery and radiation for brain metastases while systemic therapy does its job, sparing patients the side effects of local treatment.
What could go wrong
This is a small pilot study with 12 patients, so it cannot prove that surveillance is as safe as immediate local therapy. Brain metastases may grow during monitoring, and the trial tracks those safety events rather than preventing them.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with brain metastases undergoing CNS-penetrating systemic therapy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must have histologically or cytologically confirmed metastatic non-hematologic malignancy. * Patients must have at least one new or progressive brain metastasis that has not received prior local therapy (surgery or radiation therapy). * Patients must have no active brain metastasis \>3cm in size. * Leptomeningeal disease is permitted * Patients with only non-measurable disease as defined by the RANO-BM criteria are permitted so long as the clinical determination of new or progressive disease has been made by the treating team. * Patients must have no symptoms attributable to active brain metastases. * At the time of enrollment, patients must be eligible for AND planning to begin a new line of systemic therapy with potential for CNS-efficacy. Determination of potential for CNS-efficacy will be determined based on the clinical judgement of the treating physicians. Patients must have had no prior exposure to the specific systemic therapy in question at the time of enrollment, though exposure to other medications from a similar class are acceptable at the discretion of the treating team. * Patient must be planning to defer radiation therapy to trial medical therapy regardless of enrollment on trial. * Must be age ≥ 18 years. * Patients must be willing to complete MoCA and FACT-BR assessments (refer to section 4.4.1). * Performance status: KPS performance status ≥50%. * Life expectancy of ≥3 months. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * Patients who have only progressive growth of brain lesions that have previously been treated with surgery or radiation therapy. * Patients with active symptomatic brain metastases. * Patients requiring corticosteroids, anticonvulsants, or other palliative medications related to brain metastases. * Patients with conditions that exclude them from undergoing magnetic resonance imaging.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Chao Family Comprehensive Cancer Center, University of California, Irvine

    RECRUITING

    Orange, California, 92868, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.